The ~13% pricing discount signals urgency, likely tied to cash runway for phase 3 IGNYTE-3 confirmatory trial and TUDRIQEV launch costs. Monitor for insider lock-up expiry; 45-day period starts after Aug 10 prospectus supplement, first potential unlocking ~Sep 24. If stock trades above $12.06 after close, some hedge unwinding may create volatility.
Drug in focus
REPL drug pipeline →TUDRIQEV
● Neutral Named in this 8-K- Impact
- Phase
- Approved (Accelerated Approval)
- Time to market
- Already approved and commercially available in the U.S. since October 2026.
- Next catalyst
- None dated
What to watchTUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $13.67entry
- T+1 · 3mo ago −0.15%α +0.17% · $13.65
- T+5 · 3mo ago +7.02%α +7.07% · $14.63
- T+20 · 2mo ago +8.05%α +8.96% · $14.77
- T+60 · 14d ago +51.06%α +53.48% · $20.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Replimune Group priced a $150M underwritten offering of 9.7M common shares at $12.06/share and 2.7M pre-funded warrants at $12.0599/warrant. Estimated net proceeds are approximately $140.5M. The dilutive offering more than doubles the company's cash balance but adds ~18% share overhang, typical for a commercial-stage biotech funding pipeline and commercialization.
Key Facts
- Offering of 9,701,490 common shares + 2,736,340 pre-funded warrants (exercise price $0.0001)
- Aggregate gross proceeds of approximately $150M; estimated net proceeds ~$140.5M
- Offering priced at $12.06 per share, a ~13% discount to the $12.40 opening on Aug 7 pre-filing
- Underwriters: Leerink Partners, J.P. Morgan, Cantor Fitzgerald
- Closing expected August 11, 2026 with customary conditions
- 45-day lock-up on insiders from date of final prospectus supplement
Financial Impact
~$140.5M net proceeds added to cash; 9.7M new shares + 2.7M pre-funded warrant shares = 12.4M total new common-equivalent shares, ~18% dilution on ~69M est. pre-offer shares (assuming ~70M pre-offer)
Risk Factors
- 18% dilution pressures near-term EPS; no revenue data in filing to offset
- No stated use of proceeds detail, investors face uncertainty on cash burn rate allocation
- Pre-funded warrants allow immediate secondary selling at any time (ex $0.0001 exercise), adding overhang
- Biotech sector risk: confirmatory phase 3 data (IGNYTE-3) still pending; offering may signal need for more capital before readout
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093042 |
| Document: tm2622673d1_ex4-1.htm | 0001104659-26-093042 |
| Document: tm2622673d1_8k.htm | 0001104659-26-093042 |
| Document: tm2622673d1_ex99-1.htm | 0001104659-26-093042 |
| Document: tm2622673d1_ex5-1.htm | 0001104659-26-093042 |
| Document: 0001104659-26-093042-index-headers.html | 0001104659-26-093042 |
| Document: 0001104659-26-093042-index.html | 0001104659-26-093042 |
| Document: 0001104659-26-093042.txt | 0001104659-26-093042 |
Track record
32 reports on REPL
9 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 12 of 13 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers